Talaris Therapeutics - TALS Stock Forecast, Price & News

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Talaris Therapeutics Price Performance

Shares of TALS opened at $4.85 on Friday. The firm has a market cap of $201.08 million, a P/E ratio of -3.26 and a beta of 3.01. The stock has a 50 day simple moving average of $5.31 and a two-hundred day simple moving average of $7.21. Talaris Therapeutics has a 1 year low of $2.04 and a 1 year high of $17.48.

Talaris Therapeutics (NASDAQ:TALS - Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.10). On average, equities analysts anticipate that Talaris Therapeutics will post -1.8 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TALS shares. SVB Leerink cut Talaris Therapeutics from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $21.00 to $7.00 in a research report on Thursday, June 30th. Guggenheim cut their price objective on Talaris Therapeutics to $23.00 and set a "na" rating for the company in a report on Monday, May 16th. Finally, Morgan Stanley lowered Talaris Therapeutics from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $20.00 to $8.00 in a report on Tuesday, July 5th.

Insiders Place Their Bets

In other news, Director Francois Nader bought 50,000 shares of the business's stock in a transaction on Tuesday, July 19th. The stock was acquired at an average price of $3.52 per share, with a total value of $176,000.00. Following the completion of the purchase, the director now directly owns 50,000 shares in the company, valued at $176,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Scott Requadt acquired 9,444 shares of the company's stock in a transaction dated Friday, July 22nd. The stock was purchased at an average price of $3.75 per share, with a total value of $35,415.00. Following the completion of the purchase, the chief executive officer now owns 460,680 shares in the company, valued at approximately $1,727,550. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Francois Nader acquired 50,000 shares of the company's stock in a transaction dated Tuesday, July 19th. The shares were bought at an average cost of $3.52 per share, with a total value of $176,000.00. Following the purchase, the director now owns 50,000 shares of the company's stock, valued at approximately $176,000. The disclosure for this purchase can be found here. Insiders bought a total of 104,562 shares of company stock valued at $383,766 over the last quarter. 16.60% of the stock is owned by corporate insiders.